Skip to main content

Table 2 Expression of markers in luminal neoplastic cells examined by immunohistochemistry

From: Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer

  No. Grading PR ERα CK8_18 VIM CK5_6 CK14
    Percentages of + luminal epithelial cells: Mean ± SD (number of positive samples, range of positive cells)
Normal yglands 8   24 ± 24.60 (5, 25-72) 38 ± 29 (6, 22-70) 100 ± 0 (8) 100 ± 0 (8) (ductal) - 100 ± 0 (8) (terminal intralobular ducts)
Hyperpasia/ dysplasia 73   5.59 ± 17 (13, 2.10-87) 10.58 ± 25.54 (25, 1.30-100) 100 ± 0 (73) 100 ± 0 (72)c (ductal) - 100 ± 0 (29)e (terminal intralobular ducts)
Benign tumors 6   15.55 ± 17.47 (3, 27-38) 26.97 ± 38.23 (4, 6-100) 100 ± 0 (6) 42.58 ± 36.62 (5, 7.5-100) - -
Malignant tumors 68   1.54 ± 9.18 (3, 4.80-70) 2.85 ± 13.86 (6, 2-87.3) 83.45 ± 30.22 (65, 2-100) 53.19 ± 34.73 (62, 0.5-100) 7.76 ± 17.83 (29, 0.5-100) 32.05 ± 32.96 (62, 0.5-100)
DC/IDPC 8 I (1, 4.80%)a 12.38 ± 25.42 (4, 2-73) 100 ± 0 (8) 27.31 ± 28.48 (5, 17.8-80) - (1, 34%)f
Other subtypes 12 I (1, 70%)b (1, 7%)b 72.67 ± 32.35 (11, 33-100) 51.41 ± 37.74 (11, 1.2-100) 5.69 ± 16.83 (6, 5-56) 32.10 ± 36.62 (9, 0.5-100)
  22 II - - 87.18 ± 25.39 (22, 5-100) 57.85 ± 32.88 (21, 7-98) 6.98 ± 10.06 (5, 0.5-28) 37.91 ± 29.96 (22, 0.5-100)
  26 III (1, 29.70%)b (1, 87.30%)b 78.96 ± 35.79 (24, 2-100) 58.04 ± 34.80 (25, 3.3-100) 12.37 ± 25.39 (17, 0.5-100) 35.49 ± 33.84 (23, 0.5-100)
LN Metastases 9   - - 81.33 ± 35.62 (9, 2-100) 50.83 ± 42.42 (9, 0.5-98) 5.33 ± 12.16 (3, 0.5-32.7) 28.47 ± 35.47 (9, 0.5-97)
  1. SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; DC, ductal carcinoma; IDPC, intraductal papillary carcinoma; LN, lymph node; a One case of DC; bOne different case of tubulopapilary carcinoma each; cOne negative case of epitheliosis; eExclusively intralobular ducts in hyperplastic lobules were positive; fone case of DC.